Drugs / LW231
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06311734 | Jun 2022 → Jan 2024 | chronic hepatitis B virus infection | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07179575 | Oct 2025 → Mar 2027 expected | chronic hepatitis B virus infection | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LW231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311734 ↗ |
| Route | Oral | “P.O.” NCT06311734 ↗ |